OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Shares in Oxford Biomedica (OXB.L) fall as much as 12 percent after investors are spooked by a clinical update which reiterates the results of a late-stage trial where the company missed its key goal, but analysts say the move is unjustified.

"This is a classic case of the market reading the headline and not understanding the real implication of the detailed data," says Ian Wainwright, managing director of life sciences specialist sales at Canaccord Adams.

He points to the positive news in the announcement, which in fact shows that the drug may still help a subset of patients.

"I'd say the sub group analysis in the trial is actually quite positive," adds Paul Cuddon, analyst at KBC Peel Hunt, reiterating his "buy" stance.

This is actually a much better result than expected and proves Trovax has some application which could be used commercially by licensing into other therapies. The initial reaction by very few was to sell but now seeing the opportunistic buying once the news has been digested. Of course the real potentially explosive news is awaited re its development of its product for Parkinsons and Prosavin could be a Blockbuster

Prosavin Update (Oxford Biomedica)


TIDMOXB

RNS Number : 7929A
Oxford Biomedica PLC
15 October 2009

?


+---------------------------------------------------+--------------------------+
| | |
+---------------------------------------------------+--------------------------+
| For Immediate Release | 15 OCTOBER 2009 |
+---------------------------------------------------+--------------------------+


OXFORD BIOMEDICA ANNOUNCES UPDATE ON PROSAVIN PHASE I/II TRIAL IN PARKINSON'S
DISEASE AND PUBLICATION OF PRECLINICAL RESULTS
Oxford, UK - 15 October 2009: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today new data from the ongoing Phase I/II trial of
ProSavin, its novel gene therapy for the treatment of Parkinson's disease. All
patients treated at the second dose level have completed their six-month
assessments and have shown further improvement in motor function (UPDRS III
'OFF' score). The maximum improvement was 53% and the average was 34% relative
to patients' pre-treatment motor function. The Principal Investigator, Professor
Sthane Palfi of the Henri Mondor Hospital in Paris, will present interim
results from the trial at the European Society of Gene & Cell Therapy Annual
Congress, being held in Hannover, Germany, on 21-25 November 2009.


Also announced today is the publication of pivotal preclinical studies of
ProSavin, which were conducted with collaborators from the CEA/Inserm Molecular
Imaging Research Centre (MIRCen), the University of Paris XII and the Henri
Mondor Hospital, a member of the Assistance Publique Hitaux de Paris (APHP),
in France. The findings were published in the 14 October issue of the
interdisciplinary journal, Science Translational Medicine
(http://www.sciencemag.org/). The preclinical model used for these studies
simulated severe Parkinson's disease by inducing selective degeneration of
dopamine-producing neurons, which decreased dopamine to 27% of normal
concentrations. The results showed that:


ProSavin was safe and significantly increased dopamine production from
27% to 47% of normal concentrations (p < 0.05) without the addition of L-DOPA
therapy. Overall disease severity was significantly reduced by ProSavin after
six weeks (p < 0.05)
ProSavin provided sustained recovery of motor function and behaviour over
the 12-month study, which was maintained throughout a follow-up period that
concluded after 44 months. Movement and posture were significantly improved
after two weeks (p < 0.05), reaching 77% and 85% of respective normal levels
In a study of ProSavin versus oral L-DOPA therapy, both treatments
produced a similar correction of disease symptoms. However, the ProSavin group
showed no dyskinetic side-effects, whereas L-DOPA therapy induced significant
dyskinesias after two weeks (p < 0.05)
To mimic the clinical condition of patients receiving L-DOPA therapy
after ProSavin treatment, the preclinical groups were challenged with acute
systemic administration of dopaminergic agents. Both the ProSavin arm and also a
normal healthy group showed no signs of significant dyskinesias, whereas the
control arms displayed debilitating dyskinetic movements following acute
dopaminergic challenge (p < 0.05)
Another study mimicked the Phase I/II setting of treating patients with
dyskinetic side-effects caused by long-term L-DOPA therapy. In the preclinical
model, following an extended period of L-DOPA therapy, the addition of ProSavin
maintained motor function recovery with a 44% lower daily dose of L-DOPA, which
reduced dyskinesias by up to 60%


Overall, these preclinical data suggest that ProSavin may offer significant
benefit in the clinical setting, treating the primary symptoms of Parkinson's
disease as well as reducing the severe side-effects of long-term L-DOPA therapy.
These conclusions are supported by initial data from human clinical trials.


In December 2007, Oxford BioMedica initiated a dose-escalating Phase I/II study
of ProSavin in Parkinson's disease patients experiencing reduced benefit on
L-DOPA or equivalent therapies. This first-in-man study employed a similar
neurosurgical technique to the preclinical studies for administering ProSavin
directly into a region of the brain called the putamen. Two dose levels have
been evaluated to-date in cohorts of three patients per dose. The initial dose
level (1x) was based on the safe and efficacious preclinical dose, although it
was not scaled for the larger volume of the human putamen. The second dose level
represented a cautious, small increment in dose at two-fold higher (2x) than the
first dose. At both dose levels, ProSavin was safe and well tolerated with no
serious adverse events and no evidence of immunotoxicity. All patients have
shown improved motor function and quality of life, and have maintained or
reduced their L-DOPA or equivalent medication, whereas daily doses would
normally be expected to increase over this period as the disease progresses.


Recent data from the second cohort have shown further improvement in patients'
motor function at six months. The maximum improvement was 53% and the average
was 34% relative to baseline, which would be broadly equivalent to Deep Brain
Stimulation (DBS) if confirmed in placebo-controlled studies. Even with
comparable efficacy to DBS, ProSavin would represent a significant advance,
given its simpler administration with no hardware, and its potential to enhance
patients' quality of life and suppress the complications caused by oral L-DOPA
therapy.


Despite these promising results, the excellent safety profile of ProSavin
justifies further dose escalation. Allometric scaling of the highly efficacious
preclinical dose approximates to a human dose that is five-fold higher (5x) than
the initial dose. Oxford BioMedica is seeking regulatory approval to escalate
directly to a 5x dose level using a modified administration procedure that
requires fewer needle tracks and thus reduces the surgery time. Both the study's
Data Monitoring Committee and the Company's Scientific Advisory Board support
this strategy. Enhancing the efficacy of ProSavin and reducing the surgery time
could accelerate the overall development timelines and expand the market
opportunity.


Professor Sthane Palfi commented on today's news: "The preclinical
proof-of-concept studies together with clinical data from the first two dose
levels in the Phase I/II study suggest that ProSavin may provide sustained and
meaningful benefit to patients and could reduce or eliminate the debilitating
complications associated with oral dopamine replacement therapy. In the initial
indication of moderate to late-stage Parkinson's disease, ProSavin potentially
offers significant advantages to the current alternatives of Deep Brain
Stimulation or mechanical delivery of continuous dopamine."


John Dawson, Oxford BioMedica's Chief Executive Officer, added: "The recent data
from the Phase I/II study provide further evidence that ProSavin is effective at
the current dose levels. With its excellent safety profile, we have the
opportunity to escalate to a higher dose, which could be even more effective.
This would enhance the product's value and could accelerate its development. We
look forward to the presentation of interim clinical results at the upcoming
ESGCT Congress. Furthermore, the publication of our ground-breaking preclinical
results in a leading journal raises the profile of ProSavin within the medical
community and pharmaceutical industry as we prepare for larger studies and
negotiate with prospective partners."
-Ends-

270K bid @ 13p

:-)

Just when you think it cant get any better.+67%

In at 6p this will be my next 10 bagger

must have been asleep, didn't notice this increase! What fantastic news!!! should be over a 1 soon as it was in yr2000 it got to 135p nearly ten yrs ago, the Bio Sector is well and truly undervalued at present and with this news which I was hoping for early next yr, should seriously re-rate the sp.

Woaha there, whilst this is good-news it is only PhI/II - and there are plenty of failures in PhIII trials (DYOR).

Still as a bit of good-news this is most welcome, esp. as I'm nearing "evens" at about 30p - so not too far to go, bearing in mind that investors are holding onto their wallets until there is a general "feel-good" about.

However, I can't see robstuff's "...soon over1..." on the basis of this little comment.....but there may be more - this not a 1-product company AND they have plenty of Cash, after the shuffle at partners Sanoffi.

A great day todaybut I feel we need several days to get a handle on sp two companies in the last two days reported good news about PD in Phase 1 trialspeople are bound to make comparisons with pymit has been said by oxb on the August web cast/conference call re Prosavin deal JD said they were at an advanced stage of the discussions and later when pressed said that they were more advanced with one suitor than with another.it is believed oxb had the Prosavin data over a fortnight ago and could have been playing one potential partner against another in the hopes of a combined announcementmaybe?the company has been a lot higher with a lot less meat on the boneinteresting stagea nice glass beckonstoddle pip.

Guardian : " More potentially good news for sufferers of Parkinson's disease. After yesterday's announcement of successful studies for Phytopharm's Cogane treatment, comes a positive update from Oxford BioMedica.

The gene therapy company said new Phase 2 data showed patients showed improvement after receiving a second dose of its ProSavin treatment. The company said after this six month assessment there was now the opportunity to try a higher dose which could be even more effective. Meanwhile a research paper on ProSavin published yesterday in the Science Translational Medicine journal also suggested positive results from the treatment.

Much like Phytopharm yesterday, the news has lifted Oxford's shares and they are now 9p higher at 19.75p. KBC Peel Hunt issued a buy note with a 17p price target (since overtaken by the market's enthusiasm) and said:

This [data] puts the product in line with the leading gene therapy treatments in development. The therapy is potentially complementary to oral products such as Phytopharm's Cogane.

We expect a higher dose of Prosavin to be trialled shortly, with a larger number of patients before the start of Phase II/III trials. Focus is now on securing commercial partners for [cancer vaccine] Trovax and Prosavin, and time lines are uncertain."

Having read the PYM statements and OXBs OXB seems more of a breakthrough and could be used in collaborations making it very marketable and a partner agreement is likely to be announced shortly.

Wide press coverage overnght should push sp higher at the opening Fri am

Sadly the reverse is true so far !!

Oakapples142.I dont like to predict SPs but with Prosavin Hi-8Mel and Trovax deals imminentI know who wants the stock most

expect some large hdgs to be announced soon

Bingo...
RNS Number : 0232B
Oxford Biomedica PLC
19 October 2009

Barclays Global Investors Ltd
Barclays Stockbrokers Ltd
Gerrard Investment Management Ltd


Threshold(s)that is/are crossed or 6% to 7%

there's one, they didn't time it perfectly but increasing to 7% very good sign and must be confident, have we bottomed out on the profit taking? onwards upwards we hope now.

I expected this drop over the coming days as most traders are impatient and edgyas an investor I thank those traders for highlighting oxb achievementsheadline newsthey have unfortunately done their nuts from the 21p trading highand punting blind...the final few are excepting their loss as they need a stakeI would suggest others research this companyparticularly from around May.

Encouraging broker note yesterday..

ASTAIRE & CO


Subject: Oxford BioMedica (OXB.L) Moving on from a challenging year - Recommendation: BUY

Please find attached my note on Oxford BioMedica Moving on from a challenging year

Oxford BioMedica has overcome major challenges since it announced in July 2008 that its most advanced product, TroVax, was going to fail its Phase III trial. ProSavin is delivering impressive clinical results and recent data show that TroVax still has a promising commercial future. The companys financial position is sufficiently strong to allow maximisation of the value of these assets. We maintain our BUY recommendation and target price of 25p.

Valuation: The company is valued at 25p, with a market cap of 135m based on a risk-adjusted SOTP valuation, representing 85% upside, and this will increase as its products pass development milestones.

Newsflow: There is the prospect of ProSavin being out-licensed and TroVax re-starting clinical development in the coming months, both of which should cause the shares to appreciate significantly in value.

TroVax, the therapeutic cancer vaccine: The latest data from the TRIST trial indicate that the drug still has a significant commercial future, and we forecast it will generate total sales of 630m. We anticipate that TroVax will resume clinical development with the support of a clinical research organisation.

ProSavin, the Parkinsons Disease treatment: ProSavin has demonstrated in preclinical studies that it can effectively cure Parkinsons Disease, and initial data from its Phase I/II trial is confirming its potential. We believe that the product will gain further validation in the coming months from an out-licensing agreement and will go on to generate total sales of 680m.

Financial strength: The company strengthened its balance sheet with the receipt of US$26m after entering a development and commercialisation collaboration with Sanofi-Aventis and had cash reserves of 34.8m at end June 2009. It now has sufficient capital to operate into H1 2012 without any further cash inflows and we anticipate that these will increase further with licensing deals and asset sales.

Not sure I accept the findings of Astaire, they were another name that found it necessary to w*p* th* sl*t* (DYOR), can't recall their name; but maybe someone here does....

OXB is bound to fluctuate as "traders" make their money, but the hope is this stock will rise on Merit, over the next few months, but it could take a lot longer, so that itself means that any Broker comments are unlikely to refelect the L-T reality, er IMHO. I Hold.

i just came across a curiosity dated 10/10/07 .... they were assuredly stocks that someone had rated strongly for the the coming year

OXB ...... mid price then 35.75 ....... close of biz today 14.25

VIY ...... mid price then 9.25 ....... close of biz today 4.85
AZM ...... mid price then 80.0 ....... close of biz today NIL (bankrupt)
BLZ ...... mid price then 67.25 ....... close of biz today 48.0
BVC ...... mid price then 31.0 ....... close of biz today 52.5


good innit!
the only winner is BVC, which to give MRSI his due, he has always promoted.
The others are shit and worse!